Anti-platelet glycoprotein Ib alpha autoantibody (Anti-GPIbα)

Anti-platelet glycoprotein Ib alpha (GPIbα) autoantibodies are pathogenic immunoglobulins that target the GPIb-IX-V complex on the surface of platelets, specifically the von Willebrand factor (vWF) binding site (Quach et al., 2018, Blood). These antibodies are a major driver of immune thrombocytopenia (ITP), a condition characterized by low platelet counts and increased bleeding risk (Zufferey et al., 2017, Seminars in Hematology). Unlike antibodies targeting the αIIbβ3 integrin, anti-GPIbα antibodies often mediate platelet destruction through an Fc-independent mechanism; they trigger platelet activation and the loss of sialic acid (desialylation) from the platelet surface, leading to their clearance by the Ashwell-Morell receptor in the liver (Li et al., 2015, Nature Communications). This unique clearance pathway is associated with resistance to standard ITP therapies such as corticosteroids and intravenous immunoglobulin (IVIg). Therapeutic strategies to manage these autoantibodies include the use of neonatal Fc receptor (FcRn) inhibitors, such as efgartigimod, to accelerate their clearance and B-cell depleting agents like rituximab to reduce their production (Newland et al., 2022, The Lancet). Monitoring the presence and titer of these antibodies is crucial for diagnosing refractory cases and guiding personalized treatment strategies in hematology.

Other names

Anti-GPIb-IX autoantibodyAnti-CD42b antibodyPlatelet-associated IgGSoluble anti-GPIbα autoantibody

Neonatal Fc receptor (FcRn) inhibition to accelerate IgG degradation; B-cell depletion via CD20 targeting; competitive inhibition of Fc-gamma receptors on macrophages.